Список литературы

1. Swerdlow S.H., Campo E., Harris N.L., et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon 2008.

2. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860 - 1861.

3. Воробьев В.И., Кравченко С.К., Гемджян Э.Г. и др. Программное лечение первичных больных мантийноклеточной лимфомой в возрасте до 65 лет. Клиническая онкогематология. 2013. Том 6, N 3. С. 274 - 281.

4. Воробьев В.И., Лорие Ю.Ю., Мангасарова Я.К., Кравченко С.К., Кременецкая А.М. Возможности терапии рецидивов и резистентного течения лимфомы из клеток мантийной зоны. Гематология и трансфузиология. 2011. N 1: 34 - 37.

5. Поддубная И.В. Терапевтические проблемы при лимфоме зоны мантии. Современная онкология. 2010; 2: 48 - 53

6. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997; 89: 2067 - 78.

7. Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of HyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013; 24(6): 1587 - 93

8. Codet R, Mrhalova M, Krskova L, et al. Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11; 14)(q13: q32) by polymerase chain reaction and fluorescence in situ hybridization. Virchows Arch. 2003; 442: 538 - 47.

9. Coleman M, Martin P, Ruan J, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008; 112: 2228 - 2232.

10. Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol. 2009; 64: 907 - 16.

11. Corazzelli G, Russo F, Capobianco G, et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin"s lymphoma: results of a pilot study. Ann Oncol. 2006; 17 (Suppl 4): iv18 - 24.

12. Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009; 27(36): 6101 - 08.

13. Dietrich S, Tielesch B, Rieger M, et al. Patterns and Outcome of Relapse After Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. Cancer. 2010; 117(9): 1901 - 10

14. Dreyling MH, Hoster E, Van Hoof A, et al. Early Consolidation with Myeloablative Radio chemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the European MCL Network. Blood. 2008; 112: 769

15. Dreyling M, Kluin-Nelemans HC, Bea S, et al. Update on the Molecular Pathogenesis and Clinical Treatment of Mantle Cell Lymphoma: Report of the 11th Annual Conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma. 2013; 54(4): 699 - 707

16. Fenske TS, Carreras J, Zhang M, et al. Outcome of patients with mantle-cell lymphoma undergoing autologous versus reduced-intensity allogenic transplantation. Ann Oncol. 2011; 22 (Suppl. 4) Abstract 018

17. Friedberg JW, Vose JM, Kelly JL, et al. The Combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011; 117(10): 2807 - 12

18. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005; 106: 4315 - 21

19. Furtado M, Rule S. Indolent mantle cell lymphoma. Haematologica. 2011; 96(8): 1086 - 8

20. Geisler C. Front-line therapy of MCL. Hematologica. 2010; 95: 1241 - 43

21. Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012; 158(3): 355 - 62

22. Gill S, Herbert KE, Prince HM, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol. 2009; 147: 83 - 88

23. Gill S, Wolf M, Prince H, et al. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma. 2008; 8(3): 159 - 65

24. Gironella M, L-pez A, Pau A, et al. Rituximab plus gemcitabine and oxaliplatin as salvage therapy in patients with relapsed/refractory mantle-cell lymphoma ASH 54th Annual Meeting. 2012. Vol.: 120, Issue 21. Abstract # 2825.

25. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP Plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts). 2012; 120(21): Abstract 151

26. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111: 558 - 65

27. Hoster E, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood. 2008; 111: 558 - 65.

28. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002; 20: 1288 - 94

29. Kahl BS, Long WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol. 2006; 17: 1418 - 1423

30. Kluin-Nelemans JC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012; 367(6): 520 - 31

31. Komatsu H, Iida S, Yamamoto K, et al. A variant chromosome translocation at 11q13 identifying PRADl/Cyclin D1 as the BCL-1 gene. Blood. 1994; 84: 1226 - 31

32. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012; 119(9): 2093 - 9

33. Le Gouill S, N, Dhedin N, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol. 2012; 23(10): 2695 - 2703

34. Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited stage mantle cell lymphoma: Clinical outcome in patients from British Columbia. Ann Oncol. 2003; 14(10): 1555 - 61

35. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005; 23: 1984 - 92

36. Liu Z, Dong HY, Gorczyca W, et al. CD5-mantle cell lymphoma. American Journal of Clinical Pathology. 2002; 118(2): 216 - 24

37. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009; 27(8): 1209 - 13

38. Mato AR, Svoboda J, Feldman T, et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer. 2012; 118(14): 3565 - 70

39. Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012; 156(3): 346 - 53

40. Mozos A, Royo A, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclinDl-negative subtype. Haematologica. 2009; 94(11): 1555 - 62

41. Ondrejka SL, Lai R, Kumar N, et al. Indolent mantle cell leukemia: clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, к light chain restriction, and good prognosis. Haematologica. 2011; 96: 1221 - 27

42. Orchard J, Garand R, Davis Z, et al. A subset of t(11; 14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003; 101(12): 4975 - 81

43. Park BB, Kim WS, Eom HS, et al. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin"s lymphoma: a consortium for improving survival of lymphoma (CISL) trial. Invest New Drugs. 2011; 29: 154 - 60

44. Pott C, Hoster E, Beldjord K, et al. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network. Blood. 2010 (ASH Annual Meeting Abstracts); 116: Abstract 965

45. Rodriguez J, Gutierrez A, Obrador-Hevia A, et al. Therapeutic concepts in mantle cell lymphoma. Eur J Haematol. 2010; 85(5): 371 - 86

46. Rodriguez J, Gutierrez A, Palacios A, et al. Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk. Lymphoma. 2007; 48: 2172 - 78

47. Romaguera J, Fayad L, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010; 150(2): 200 - 08

48. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, Phase 3 non-inferiority Trial. Lancet. 2013; 381(9873): 1203 - 10

49. Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma Annals of Oncology. 2010; 21: 133 - 39

50. Smithers DW. Summary of papers delivered at the Conference on Staging in Hodgkin"s Disease (Ann Arbor). Cancer Res. 1971; 31(11): 1869 - 70

51. Spurgeon SE, PindyckT, Okada C, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma. 2011; 52: 1488 - 1494

52. Sun T, Nordberg M, Cotelingam J, et al. Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma. Am J Hematol. 2003; 74(1): 78 - 84

53. Swerdlow S, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (International Agency for Research on Cancer (IARC)) 4th ed., 2008.

54. Tam C, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009; 113(18): 4144 - 52

55. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005; 131(1): 29 - 38

56. Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013; 31(11): 1442 - 49

57. Wang M, Rule SA, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6): 507 - 16

58. Wlodarska I, Meeus P, Stul M, et al. Variant t(2; 11)(p11; q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. Leukemia. 2004; 18: 1705 - 10

59. Yatabe Y, Suzuki R, Matsuno Y, et al. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: Study of 168 cases. Pathology International. 2001; 51: 747 - 61

60. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000; 95: 2253 - 61

61. Zhou Y, Wang H, Fang W, et al. Incidence Trends of Mantle Cell Lymphoma in the United States Between 1992 and 2004. Cancer. 2008; 113: 791 - 8.

62. Spurgeon SE, Pindyck T, Okada C, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma. 2011; 52: 1488 - 1494

63. Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011; 118: 3419 - 25

64. Ruan J, Martin P, Coleman M, et al. Durable Responses with the Metronomic Regimen RT-PEPC in Elderly Patients with Recurrent Mantle Cell Lymphoma. Cancer. 2010; 116(11): 2655 - 64.

65. Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016 Jul 5. [Epub ahead of print].

66. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016; 387(10020): 770 - 8

67. Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(1): 48 - 56

68. Mato R, Svoboda J, Feldman T, et al. Post-Treatment (Not Interim) Positron Emission Tomography-Computed Tomography Scan Status Is Highly Predictive of Outcome in Mantle Cell Lymphoma Patients Treated With R-HyperCVAD. Cancer. Volume 118, Issue 14.

69. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126: 739 - 45

70. Chihara D, Cheah CY, Westin JR, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016; 172(1): 80 - 8